Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.57 |
| ▸ | LIMK2 | P53671 | 7/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.45 |
| ▸ | PRKACA | P17612 | 2/20 | 0.45 |
| ▸ | PRKACG | P22612 | 2/20 | 0.45 |
| ▸ | PRKACB | P22694 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726023 | 1.00 | AKT1 (0.57) | AKT1LIMK2ROCK2LIMK1PRKACA | |
| SCHEMBL4776933 | 1.00 | AKT1 (0.57) | AKT1LIMK2ROCK2LIMK1PRKACA | |
| SCHEMBL4778647 | 0.90 | AKT1 (0.54) | AKT1 | |
| SCHEMBL4726156 | 0.87 | AKT1 (0.54) | AKT1LIMK2ROCK2LIMK1ROCK1 | |
| SCHEMBL4778339 | 0.86 | LIMK2 (0.54) | AKT1LIMK2ROCK2LIMK1PRKACA | |
| SCHEMBL4780166 | 0.85 | AKT1 (0.63) | AKT1LIMK2ROCK2LIMK1PRKACA | |
| SCHEMBL4725174 | 0.85 | AKT1 (0.63) | AKT1LIMK2ROCK2LIMK1PRKACA | |
| SCHEMBL4725968 | 0.84 | AKT1 (0.57) | AKT1LIMK2ROCK2LIMK1PRKACA | |
| SCHEMBL4778804 | 0.84 | AKT1 (0.52) | AKT1LIMK2ROCK2LIMK1PRKACA | |
| SCHEMBL4727942 | 0.84 | AKT1 (0.56) | AKT1LIMK2ROCK2LIMK1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT1 752/4885LIMK2 1823/4885ROCK2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.